Skip Navigation
Skip Website Tools

Online Screener

Healthy people can help us better understand, treat, and prevent diseases. Complete an online screener if you want to volunteer for a clinical research study.​​​

FACT: People born from 1945 - 1965 are 5 times more likely to be infected with Hepatitis C.  Learn more:

NIAID HIV and Emerging Infectious Diseases Program

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Viral Hepatitis Studies

The National Institutes of Health (NIH) houses the nation’s most renowned biomedical research institutions. The following clinical research studies are being conducted by NIAID and the NIH Clinical Center in Bethesda, Maryland:

Safety, Tolerability, and Efficacy of Daclatasvir and Asunaprevir, with or without BMS-791325, in Subjects Coinfected with HIV- HCV

(CONQUER 14-CC-0065)

You are being asked to participate in this study because you have HIV infection and liver disease caused by infection with hepatitis C virus (HCV). Your blood tests show that the HCV infection continues to be a problem (i.e., the virus continues to reproduce), causing a chronic infection. Currently there are about 4 million people with HCV in the US and only about 10 – 20% are being treated for their HCV.

​Daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 are new oral medications being developed for the treatment of HCV infection. They are still being researched and are not approved by the Food and Drug Administration (FDA). This combination of ASV, DCV and BMS-791325 has never been given to individuals with both HIV and HCV infection. The purpose of this study is to determine whether this combination of drugs for 12 weeks can be safe and effective for treating HCV infection in people who also have HIV infection.  Volunteer compensation and study medications will be provided.

Last Updated February 13, 2015